# Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

> **NCT07023835** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Zydus Therapeutics Inc.** · enrollment: 240 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** 50 mg Usnoflast
- **DRUG:** 75 mg Usnoflast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07023835
- **Lead sponsor:** Zydus Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-17
- **Primary completion:** 2028-03
- **Final completion:** 2028-10
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07023835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07023835, "Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07023835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*